Nisa Investment Advisors
STLN

Nisa Investment Advisors’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Nisa Investment Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13
Closed – – 2708
2022
Q4 		$0 Buy
+13
New +$36 ﹤0.01% 2728

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Nisa Investment Advisors's STLN Position: Q1 2023 in Review

Nisa Investment Advisors sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2023, closing a stake of 13 shares.

Nisa Investment Advisors first reported a position in STLN in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 39 funds tracked by Wall St. Rank hold STLN as of Q1 2023.

  • Nisa Investment Advisors reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Nisa Investment Advisors sold 13 Starling Oncology Institute, Inc. Common Stock shares in Q1 2023.
  • Nisa Investment Advisors first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Nisa Investment Advisors's Starling Oncology Institute, Inc. Common Stock position peaked at $0 in Q4 2022.
  • 39 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2023.

Based on Nisa Investment Advisors's 13F filing for Q1 2023, filed 2 May 2023.